Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis

World Journal of Gastroenterology

Volumn 21, Issue 9, 2015, Pages 2807-2815

  Yang, Jian Jun ^a   Hu, Zhi Gao ^a   Shi, Wu Xiang ^a   Deng, Te ^a   He, Song Qing ^a,b   Yuan, Sheng Guang ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair   (China)

Author keywords

Cancer specific survival; Clinicopathological features; Meta analysis; Neutrophil to lymphocyte ratio; Overall survival; Pancreatic cancer

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ALBUMIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONSENSUS; DISEASE FREE SURVIVAL; FEMALE; HAZARD RATIO; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; META ANALYSIS; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; QUALITY CONTROL; SAMPLE SIZE; SURVIVAL RATE; TUMOR DIFFERENTIATION; IMMUNOLOGY; LYMPHOCYTE; MORTALITY; NEUTROPHIL; ODDS RATIO; PANCREATIC NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; NEUTROPHILS; ODDS RATIO; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925381613     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i9.2807     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138].
2. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-620 [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0].
3. Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol 2014; 7: 55-64 [PMID: 24772208].
4. Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Telek B, Ba'ssalamah A, Stift J, Schoppmann SF, Gnant M. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Anticancer Res 2014; 34: 2377-2384 [PMID: 24778046].
5. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y, Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-618 [PMID: 22194634 DOI: 10.1373/clinchem.2011.172767].
6. Hagihara A, Hiraoka S, Ikeda M, Ueno H, Machey JR, Okusaka T, Morizane C, Kondo S, Sakamoto Y, Shimada K, Esaki M, Nara S, Kosuge T. hENT 1 Expression Might Be a Useful Biomarker to Predict Prognosis in Patients With Resected Pancreatic Cancer. Pancreas 2009; 38: 999-1000.
7. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; 6: e1000046 [PMID: 19360088 DOI: 10.1371/journal.pmed.1000046].
8. Chung HW, Lim JB. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J Transl Med 2014; 12: 102 [PMID: 24745825 DOI: 10.1186/1479-5876-12-102].
9. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013; 25: 50-51 [PMID: 23150341 DOI: 10.1097/CCO.0b013e32835b651e].
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013].
11. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190 [PMID: 10646872].
12. Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 2014; 110: 183-188 [PMID: 24201751 DOI: 10.1038/bjc.2013.701].
13. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One 2014; 9: e92079 [PMID: 24642859 DOI: 10.1371/journal.pone.0092079].
14. Nakagawa K, Tanaka K, Nojiri K, Kumamoto T, Takeda K, Ueda M, Endo I. The modified Glasgow prognostic score as a predictor of survival after hepatectomy for colorectal liver metastases. Ann Surg Oncol 2014; 21: 1711-1718 [PMID: 24452408 DOI: 10.1245/s10434-013-3342-6].
15. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pretreatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58: 15-23 [PMID: 18414853 DOI: 10.1007/s00262-008-0516-3].
16. Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M, Gumus M. The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010; 27: 1060-1065 [PMID: 19847679 DOI: 10.1007/s12032-009-9335-4].
17. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y. Prognostic role of neutrophilto-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 2014; 134: 2403-2413 [PMID: 24122750 DOI: 10.1002/ijc.28536].
18. Wells GASB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies inmeta-analyses: Available from: URL: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16 [PMID: 17555582 DOI: 10.1186/1745-6215-8-16].
20. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 2011; 35: 868-872 [PMID: 21312035 DOI: 10.1007/s00268-011-0984-z].
21. Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J 2014; 44: 676-682 [PMID: 24750233 DOI: 10.1111/imj.12453].
22. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 2012; 29: 3092-3100 [PMID: 22476808 DOI: 10.1007/s12032-012-0226-8].
23. Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 2014; 3: 406-415 [PMID: 24519894 DOI: 10.1002/cam4.204].
24. Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Okamura Y. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma. Ann Surg Oncol 2013; 20: 4330-4337 [PMID: 23982254 DOI: 10.1245/s10434-013-3227-8].
25. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203 [PMID: 20122680 DOI: 10.1016/j.amjsurg.2009.08.041].
26. Aliustaoglu M, Bilici A, Seker M, Dane F, Gocun M, Konya V, Ustaalioglu BB, Gumus M. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 2010; 57: 640-645 [PMID: 20698242].
27. Teo M, Mohd Sharial MS, McDonnell F, Conlon KC, Ridgway PF, McDermott RS. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. Tumori 2013; 99: 516-522 [PMID: 24326841 DOI: 10.1700/1361.15104].
28. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010; 15: 516-522 [PMID: 20602543 DOI: 10.3109/1354750x.2010.491557].
29. Szkandera J, Stotz M, Eisner F, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One 2013; 8: e78225 [PMID: 24223776 DOI: 10.1371/journal.pone.0078225].
30. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophillymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109: 416-421 [PMID: 23799847 DOI: 10.1038/bjc.2013.332].
31. Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol 1992; 22: 256-263 [PMID: 1331571].
32. Yamashita J, Ogawa M, Shirakusa T. Free-form neutrophil elastase is an independent marker predicting recurrence in primary breast cancer. J Leukoc Biol 1995; 57: 375-378 [PMID: 7884307].
33. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/s0140-6736(00)04046-0]
34. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283-287 [PMID: 15166496].
35. Salazar-Onfray F, López MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182 [PMID: 17329145 DOI: 10.1016/j.cytogfr.2007.01.015].
36. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999; 155: 537-547 [PMID: 10433946].
37. Hirano A, Zimmerman HM, Levine S. The fine structure of cerebral fluid accumulation. IX. Edema following silver nitrate implantation. Am J Pathol 1965; 47: 537-548 [PMID: 5837731].
38. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148 [PMID: 15308095 DOI: 10.1016/j.immuni.2004.07.017].
39. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384 [PMID: 11357146 DOI: 10.1038/35077246].
40. Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 2011; 60: 819-827 [PMID: 21373990 DOI: 10.1007/s00262-011-0996-4].
41. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-28 [PMID: 16340740].
42. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922 [PMID: 12396713 DOI: 10.1089/10799900260286623].
43. Yi JH, Wang D, Li ZY, Hu J, Niu XF, Liu XL. C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review. PLoS One 2014; 9: e94632 [PMID: 24800842 DOI: 10.1371/journal.pone.0094632].
44. Liu ZQ, Chu L, Fang JM, Zhang X, Zhao HX, Chen YJ, Xu Q. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014; 16: 467-471 [PMID: 24589465 DOI: 10.4103/1008-682x.123686].
45. Zheng Z, Zhou L, Gao S, Yang Z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci 2013; 10: 653-664 [PMID: 23569429 DOI: 10.7150/ijms.6050].
46. Stenman M, Laurell A, Lindskog M. Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Med Oncol 2014; 31: 841 [PMID: 24477648 DOI: 10.1007/s12032-014-0841-7].
47. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39: 534-540 [PMID: 22995477 DOI: 10.1016/j.ctrv.2012.08.003].
48. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-226 [PMID: 19318937 DOI: 10.1097/MCO.0b013e32832a7902].
49. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699 [PMID: 22828611 DOI: 10.1038/bjc.2012.292].